Neuromeka Co., Ltd.

As of June 30, 2026, Neuromeka Co., Ltd. carries a market capitalization of 520.42B, placing it among publicly traded companies globally. Its enterprise value stands at 556.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neuromeka Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Neuromeka Co., Ltd. has 20.71M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.66, and the price-to-book ratio stands at 14.30.

These figures are as of June 30, 2026. The EV/Sales ratio of 30.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 556.75B versus a market cap of 520.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Neuromeka Co., Ltd. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 132.09, indicating elevated leverage, while an interest coverage ratio of -6.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neuromeka Co., Ltd. posted a negative return on equity (ROE) of -146.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.01, reflecting losses generated across the asset base. The company generates approximately 117.90M in revenue per employee across its workforce of 154.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.52 indicates how many times Neuromeka Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Neuromeka Co., Ltd.'s stock has declined approximately 0.03% over the past 52 weeks. The 50-day moving average sits at 19,169.80, while the 200-day moving average is 30,919.73.

Over the twelve months ended June 30, 2026, Neuromeka Co., Ltd. generated 18.16B in revenue and converted that into -40.14B in net income, yielding earnings per share of -2,093.28. EBITDA reached -13.23B, while operating income came in at -16.25B.

As of June 30, 2026, Neuromeka Co., Ltd. holds 13.40B in cash and equivalents against 49.02B in total debt, resulting in a net debt position of 37.82B. Total book value stands at 36.38B, with working capital of -12.24B providing operational flexibility.

Neuromeka Co., Ltd. produced -18.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.60B in capital expenditures, free cash flow totaled -24.16B - equivalent to -1,254.55 per share.

Over the twelve months ended June 30, 2026, Neuromeka Co., Ltd. posted a gross margin of 19.36, reflecting its pricing power and cost economics. The operating margin of -89.48 and net profit margin of -221.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.24, meaning Neuromeka Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Neuromeka Co., Ltd.'s most recent stock split took place on August 5, 2026 with a 2:3 split ratio.

As of June 30, 2026, Neuromeka Co., Ltd. has an Altman Z-Score of 3.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.